Allergan, Inc. (NYSE:AGN)

CAPS Rating: 4 out of 5

A technology-driven, global health care company which discovers, develops and commercializes pharmaceutical and medical device products for markets such as ophthalmic, neurological, medical aesthetics, medical dermatological etc.

Results 1 - 20 of 54 : 1 2 3 Next »

Recs

0
Member Avatar huddaman (97.35) Submitted: 9/24/2013 3:27:46 PM : Outperform Start Price: $91.41 AGN Score: +36.78

M* Wide Pick

Recs

0
Member Avatar pramathmalik (36.87) Submitted: 8/2/2013 5:32:02 PM : Outperform Start Price: $91.37 AGN Score: +37.30

Cramer - Apparently has a good product, outperforming industry slightly and ability to block generics

Recs

0
Member Avatar wtcrane1 (94.19) Submitted: 7/18/2013 4:41:37 PM : Outperform Start Price: $91.85 AGN Score: +35.19

undervalued

Recs

0
Member Avatar JorgeAura (< 20) Submitted: 2/2/2013 7:16:27 PM : Underperform Start Price: $105.99 AGN Score: -2.36

sp500 in maximums.

Recs

0
Member Avatar JasonLaub (< 20) Submitted: 1/29/2013 1:14:36 AM : Outperform Start Price: $106.13 AGN Score: +1.73

Strong growth in multiple markets, especially in Botox - it was recently approved to treat overactive bladder.

Recs

0
Member Avatar ikkyu2 (99.38) Submitted: 3/12/2012 7:12:19 PM : Outperform Start Price: $91.46 AGN Score: +11.67

BoTox is a verb and is the only FDA-approved treatment for chronic migraine, which is maybe the #2 or #3 contributor of lost work days in the country. And it actually works. I don't think Allergan can help but grow earnings from here.

Recs

0
Member Avatar NevDullNJ (< 20) Submitted: 2/8/2012 1:22:22 PM : Outperform Start Price: $88.70 AGN Score: +12.74

Many of Allergan's products are tied to the notion of "you, just better". As we're entering this "halftime in America" period, if we'll be doing better we'll want to feel better about ourselves, and AGN will be there to take our money.

Recs

0
Member Avatar daviddeweaver (< 20) Submitted: 2/20/2011 12:24:18 PM : Outperform Start Price: $73.71 AGN Score: +41.66

The trend for the past year on AGN seems to show that over the long run the stock has a lot of faith from investors, and over time it produces consistent gains. However, the faith in the company will seem rather unjustified in a couple of years, which will not necessarily mean a downturn in price, but it will no longer outperform the market.

Recs

0
Member Avatar oldmanarchitect (< 20) Submitted: 12/10/2010 7:08:21 AM : Outperform Start Price: $68.51 AGN Score: +45.33

The Lap Band will soon be approved for obesity, rather than limited to morbidly obese. Procedure has only been used on 300,000 patients so far and makes up a rather small portion of the AGN profits. Foresee Lap Band profits doubling within the next 5 years.

Botox will continue its domination of market share, and with new procedural uses coming on line (Migraine, seizure) - Botox will double use within next three years

Recs

0
Member Avatar stuinkc (76.55) Submitted: 11/4/2010 4:56:56 PM : Outperform Start Price: $72.77 AGN Score: +31.68

You're so vain, you probably think this song is about you....

Recs

0
Member Avatar dkraljic (< 20) Submitted: 8/8/2010 9:09:39 AM : Outperform Start Price: $64.28 AGN Score: +43.26

Botox is already hot. Latisse is moving ahead strongly. And Botox indication for Migraine is pending approval.

Recs

0
Member Avatar foolontherocks (88.25) Submitted: 12/18/2009 1:24:27 AM : Outperform Start Price: $59.78 AGN Score: +54.87

botox will stay popular

Recs

0
Member Avatar COOLSTOCK (71.16) Submitted: 6/12/2009 11:00:44 AM : Outperform Start Price: $45.14 AGN Score: +97.47

good company

Recs

0
Member Avatar akdag (< 20) Submitted: 2/26/2009 10:31:48 AM : Outperform Start Price: $40.45 AGN Score: +103.76

Very successful product line with not much comparable competition (Botox, Juvederm). They also developed less expensive and evasive procedures like eye lash treatments. Especially during tough eco times personal (and more affordable) luxuries like the lash and various derma treatments will allow revenue targets being met. AGN will be doing fine b/c of the current economy.

Recs

0
Member Avatar sashamore (65.06) Submitted: 12/31/2008 12:24:19 PM : Outperform Start Price: $39.43 AGN Score: +128.83

great new cosmetic product approved by fda will increase sales

Recs

0
Member Avatar dissinj (< 20) Submitted: 12/4/2008 4:04:56 PM : Outperform Start Price: $35.48 AGN Score: +148.62

The potential that Lumigan will explode profits with little in the way of adverse events. A real positive for a Pharma company.

Recs

0
Member Avatar mukwonago53149 (< 20) Submitted: 12/3/2008 8:30:27 PM : Outperform Start Price: $36.37 AGN Score: +145.86

http://www.thestreet.com/story/10451209/1/cramers-mad-money-recap-let-the-deals-begin.html?puc=_htmlbooyah

Recs

0
Member Avatar MViscio1 (99.62) Submitted: 10/23/2008 11:57:41 AM : Outperform Start Price: $35.17 AGN Score: +170.10

HEALTH CARE COMPANY

Recs

0
Member Avatar JoyofMoney (72.15) Submitted: 7/9/2008 2:32:51 AM : Outperform Start Price: $51.51 AGN Score: +110.84

Terrible P/E ratios but the rest of the fundamentals were good enough to sell me. Medical devices, a complement to pharmaceutical as well as a specialty pharmaceutical niche. Had narrow movement in stock price in the past few weeks and I liked the price being toward its 52 week low. Optimistically, I am looking for strength out of this one in a market that is volatile.

Recs

0
Member Avatar biovestor (< 20) Submitted: 6/28/2008 10:29:35 AM : Outperform Start Price: $50.91 AGN Score: +112.73

A leader in cosmetic medicine in a US market obsessed with appearance and a growing Baby Boomer population.

Results 1 - 20 of 54 : 1 2 3 Next »

Featured Broker Partners


Advertisement